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Abstract
Background and Aim: Management of hepatitis C virus (HCV) recurrence is a major
challenge after liver transplantation. Significant dysregulated expression of HCV receptors
(i.e. claudin-1, occludin, tetraspanin CD81, scavenger receptor type B1) has been shown
recently during HCV infection. This might facilitate hepatocytic entry and reinfection of
HCV. MicroRNAs (miRs) play role in the regulation of gene expression. We aimed
to characterize miR expression profiles related to HCV infection and antiviral therapy in
adult liver transplant recipients, with special emphasis on miRs predicted to target HCV
receptors.
Methods: Twenty-eight adult liver transplant recipients were enrolled in the study. Paired
biopsies were obtained at the time of HCV recurrence and at the end of antiviral treatment.
MiRs for HCV receptors were selected using target prediction software. Expression levels
of miR-21, miR-23a miR-34a, miR-96, miR-99a*, miR-122, miR-125b, miR-181a-2*,
miR-194, miR-195, miR-217, miR-221, and miR-224 were determined by reverse
transcription–quantitative polymerase chain reaction.
Results: miR-99a* and miR-224 expressions were increased in HCV recurrence samples,
while miR-21 and miR-194 were decreased in comparison to normal liver tissue. Increased
expressions of miR-221, miR-224, and miR-217 were observed in samples taken after
antiviral therapy when compared with HCV recurrence samples. High HCV titer at recur-
rence was associated with higher level of miR-122.
Conclusions: Samples at recurrence of HCV and after antiviral therapy revealed distinct
HCV-related miR expression profiles, with significant dysregulation of those miRNAs
potentially targeting mRNAs of HCV receptors. In particular, miR-194 and miR-21 might
be involved in the regulation of HCV receptor proteins’ expression during HCV infection
and antiviral therapy.
Introduction
Hepatitis C virus (HCV) infection-related chronic liver disease
is a significant health problem worldwide and is the leading
indication for orthotopic liver transplantation (OLT).1,2 HCV
recurrence after transplantation is universal and represents a
major therapeutic challenge as current standard therapy against
HCV infection is limited to the combination of pegylated
interferon-α and ribavirin (IFN/RBV). However, the therapy has
considerable side-effects, and the response rate is less than
ideal.3
Several cellular factors are known to be involved in the hepato-
cellular entry mechanism of HCV.4 Tight-junction (TJ) proteins
claudin-1 (CLDN1) and occludin (OCLN), CD81, scavenger
receptor class B type 1 (SCARB1) have been reported to be part of
the internalization complex and are essential for HCV entry both
in vitro and in vivo.2,5–7
Previous studies have shown discrepancies between messenger
RNA (mRNA) and protein expression levels of these receptors
in HCV infected patients, suggesting therefore the role of
microRNAs (miRs) in the modulation of gene expression.2,4,5
MiRs are small endogenous non-coding ∼22 nucleotide long
RNAs that regulate gene expression at posttranscriptional level.
MiRs induce degradation of the mRNA or suppression of
protein translation upon binding to the 3′ untranslated regions
(UTRs) of an mRNA.8,9 One microRNA sequence might interact
with several mRNAs. Therefore, miRs exert negative regulation
on mRNA and finally on protein expression. They are essential
for maintenance of cellular homeostasis and normal func-
tion, serving as key regulators of various biological processes
doi:10.1111/jgh.12362
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including cellular stress, steatosis, proliferation, differentiation,
and apoptosis.9–11
Dysregulated expression of miRs might play role in the
development of many diseases including viral infections and
malignancies.12–14 MiRs also participate in the control of HCV
infection as well as in the IFN pathway via several mecha-
nisms.3,15 The liver-specific microRNA, miR-122, is known as
a positive cofactor in HCV replication cycle16 and has been
found to be downregulated by α/β IFNs.17 Besides, IFN-β has
been described as modulator of the expression of several miRs
having sequence-predicted targets within the HCV genomic
RNA, and some of these miRs were shown to actively inhibit
HCV replication.17,18 In addition, the hepatic microRNA expres-
sion pattern existing in chronic HCV-infected patients before
antiviral therapy was shown to be associated with therapy
response.3
The aim of the current study was to evaluate the expression of
miRs, which either have one of the HCV receptors among their
target mRNAs according to target prediction software (such as
miR-21, miR-34a, miR-96, miR-125b, miR-194, miR-195, and
miR-224), or which may play role in HCV infection or in antiviral
treatment response (such as miR-23a, miR-99a*, miR-122, miR-
181a-2*, miR-217, and miR-221) in liver transplant recipients.
Materials and methods
Patients and sample preparation. A total of 28 liver
needle biopsies of HCV-positive adult liver transplanted patients
were included. These selection criteria were applied: (i) HCV-
related cirrhosis and subsequent liver transplantation; (ii) histo-
logically proved recurrence followed by completed 12 months
uninterrupted antiviral therapy; (iii) 6 months follow up after
antiviral therapy.
Baseline characteristics of patients are summarized in Table 1.
In the majority of patients (n = 22, 78.6%), HCV recurred within
the first postoperative year. Liver biopsies were taken twice: at the
time when HCV recurrence was observed following liver trans-
plantation and after the end of antiviral therapy. Normal liver
samples (n = 13) were obtained from deceased donors during
organ receiving, just before ligation of the abdominal aorta and
reperfusion. These donor livers were used for transplantation
before the start of this project. Liver samples were fixed in 10%
buffered formalin and embedded in paraffin. HAI (histology activ-
ity index, modified ISHAK score /0–18/) and fibrosis score /0–6/
were determined for histological grading and staging of liver
specimens. The study followed the ethical guidelines of the 1975
Declaration of Helsinki. Informed consent was obtained from all
patients included in the study.
Treatment protocol and definitions of therapy response.
All selected patients received the combination of IFN/RBV for 12
months without interruption. Patients with good renal function
received pegylated IFN 2b, while patients with impaired renal
function were treated with pegylated IFN 2a. No additional treat-
ment was applied. Six patients (21%) achieved sustained viral
response (SVR: HCV was undetectable in the sera using reverse
transcription–polymerase chain reaction [RT-PCR] 6 months fol-
lowing the completion of IFN/RBV therapy). Patients were
defined as being non-responders (NR) if their sera were positive
for HCV RNA (22 patients). All patients had HCV genotype 1b
infection. There were no significant differences in patient gender
or age between the NR and SVR groups.
MicroRNA target prediction. In silico identification of
miRs that may bind to any mRNAs of HCV receptors CLDN1,
OCLN, SCARB1, and CD81 was performed using microRNA.org
(http://www.microrna.org) target prediction database and soft-
ware application developed by Tömböl and coworkers.19 The
latter is capable of merging three target prediction databases
such as TargetScan 6.0 (http://www.targetscan.org), PicTar
(http://pictar.mdc-berlin.de), and MicroCosm Targets Version 5
(http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/).
The database search resulted in about 550 specific miRs, from
which there were 39 (CLDN1), 13 (OCLN), 1 (miR-194; CD81),
and 8 (SCARB1) miRs commonly present in the database lists
for the four mRNAs, respectively. Finally, the microRNA lists
were narrowed down by either selecting the consensus sequences
of all three databases or the sequences possibly targeting several
mRNAs of different HCV receptor types, or mRNAs connected
to HCV hepatitis according to the literature. The following miRs
were selected to modulate HCV receptor expression by target
prediction and based on sequence homology: CLDN1: 21, 34a,
96, 194, and 195; OCLN: 122, 194, and 224; CD81: 23a, 125b,
and 194; SCARB1: 96, 99a*, 125b, and 195 (Letters in bold
indicate consensus in all three databases).
RNA extraction and RT-quantitative PCR. RNA was iso-
lated using RNeasy FFPE Mini Kit (QIAGEN, Hilden, Germany)
according to the manufacturer’s instructions with modification for
copurification of miRNA, then stored at −80°C. Contaminating
genomic DNA was removed using Turbo DNase digestion
(Ambion Life Technologies, Carlsbad, CA, USA) according to the
manufacturer’s instructions.
Table 1 Baseline characteristics of patients
Age 50 ± 5.4
Gender (male/female) 18/10
MELD score 13.5 ± 5
HCV RNA (106/mL) at recurrence 8.2 ± 10.7
HCV RNA (106/mL) after therapy 1.9 ± 4.5
Tacrolimus based IS 20 (71.4%)
Cyclosporin A IS 8 (28.6%)
HAI (Knodell score) 1–8
At recurrence 1–4/5–8 21/7
After therapy 1–4/5–8 27/1
Fibrosis score 0–6
At recurrence 0–1/2–3/4–6 21/6/1




HAI, histology activity index; HCV, hepatitis C virus; IS, immunosuppres-
sion; MELD, model for end-stage liver disease; NR, non-responder; SVR,
sustained virological response.
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MicroRNA expression was determined applying the following
TaqMan MicroRNA Assays (Applied Biosystems, Carlsbad,
CA, USA): miR-21 (ID:000397), miR-23a (ID:000399), miR-34a
(ID:000426), miR-96 (ID:000186), miR-99a* (ID:002141),
miR-122 (ID:002245), miR-125b (ID:000449), miR-181a-2*
(ID:002317), miR-194 (ID:000493), miR-195 (ID:000494),
miR-217 (ID:002337), miR-221 (ID000524), and miR-224
(ID:002099). RT was performed using TaqMan MicroRNA
Reverse Transcription Kit (Applied Biosystems) according to the
manufacturer’s instructions in 7.5 μL final volume containing
10 ng total RNA. TaqMan Universal PCR Master Mix No
AmpErase UNG (Applied Biosystems) was applied for real-time
PCR, also carried out according to the manufacturer’s instructions,
in 10 μL final volume containing 0.65 μL RT product. The reaction
was run on an ABI PRISM 7000 system (Applied Biosystems).
The samples were measured in duplicates. Relative expression
level in samples was determined by 2ΔCq method using the mean
Cq value of miR-23a and miR-34a as reference. These reference
miRs showing the overall least variation among samples were
selected using NormFinder20 as U6 snRNA (ID:001973) proved to
be highly variable in the samples.
Statistical analysis. SPSS 15. version (SPSS, Inc., Chicago,
IL, USA) was used for the statistical analysis. Continuous vari-
ables are shown as mean values and standard deviations. Student’s
t-test, anova test with Scheefe and Bonferroni post hoc tests, as
well as Mann–Whitney U-test were utilized for univariate analy-
ses, after examining population homogeneity of the variables
(Levene test). The anovamethod was used to compare microRNA
expression before and after IFN therapy, when therapy response
(SVR vs NR) was taken into account. The connections between
continuous variables were evaluated by correlation analysis,
using Pearson correlation coefficient. P < 0.05 was considered
significant.
Results
Baseline characteristics of patients are shown in Table 1. Exami-
nation of the clinical data revealed that post-treatment viral load
decreased significantly only in the SVR group when compared
with pretreatment levels (12 × 106 /mL ± 15.7 vs 0/mL, P =
0.003). HAI decreased in both NR (3.74 ± 1 vs 1.6 ± 1,
P < 0.0001) and SVR groups (4 ± 1 vs 1 ± 1.3, P = 0.002) after
administering IFN/RBV therapy. After finishing antiviral therapy
fibrosis score was analyzed, and no correlation was found between
fibrosis being above or below the median (fibrosis score 1) and the
investigated miRs. High viral load (above median 3.4 × 106/mL)
at the time of HCV recurrence was associated with higher
expression level of miR-122 (relative expression below median
132.8 ± 79 vs above median 2252.6 ± 2663, P = 0.025). The
expression level of miR-221 negatively correlated with HAI
(r = −0.313, P = 0.036).
The transcriptional levels of miR-99a* and miR-224 were sig-
nificantly increased, while miR-21 and miR-194 were decreased in
liver samples obtained at HCV recurrence, as compared with the
levels measured in normal liver tissue. Results are shown in
Table 2a and Figure 1a.
To examine whether IFN/RBV therapy has impact on
microRNA expression after OLT, we compared paired liver
samples of patients obtained before and after antiviral treatment.
In comparison with pretreatment expression levels, increased
expressions were found for miR-221, miR-224, and miR-217 in
samples taken after administration of antiviral treatment (Table 2b
and Fig. 1b.).
MicroRNA expression levels were also investigated in relation
to therapy response. Because of the fact that only SVR is associ-
ated with long-term clinical improvement, we focused on this
patient group (n = 6; 21%). SVR patients showed significantly
increased miR-96, miR-99a*, miR-122, miR-181a-2*, miR-217,
and miR-221 expression levels in comparison with non-responders
at the end of aniviral therapy (Table 2c and Fig. 1c.). Among SVR
patients, a significant upregulation of miR-221 (0.664 ± 0.82
before vs 6.728 ± 10 after, P = 0.017) and miR-122 (1557.6 ±
3005 before vs 11 103.8 ± 16666 after, P = 0.038) was observed at
the end of the treatment. The pretreatment microRNA profile was
not predictive for the success of antiviral therapy.
Discussion
The recurrence of HCV is related to lower survival rates after liver
transplantation.21 Moreover, disease progression is accelerated
after OLT because of the immunsuppressed status of the patients.22
Current standard IFN/RBV therapy against HCV is known to be
effective in only 50% of patients infected with the prevalent geno-
type 1.23 HCV recurrence in liver-transplanted patients is therefore
a suitable model to study the pathomechanism of HCV reinfection
and the effect and outcome of antiviral therapy.
This is the first study examining the expression of miRs target-
ing HCV receptors in liver transplant patients due to chronic HCV-
induced liver failure. The miRs were selected on the basis of in
silico target prediction, focusing on HCV receptors.
After non-specific attachment to the cell surface molecules such
as low-density lipoprotein receptors and glycosaminoglicans,
HCV particles are consecutively bound to a complex formed by
SCARB-1 and CD81. Virus associated with CD81 would then be
transferred into TJs, where HCV would interact with CLDN-1 and
OCLN to enter the cell.2 The expression of CLDN-1 and OCLN
proteins is increased in HCV-infected liver compared with normal
liver tissue4,5 and in HCV recurrence after OLT.2 However, there
was no correlation between mRNA and protein levels of these
receptors.2 Similarly, in a recent paper by Nakamuta and col-
leagues, different mRNA and protein expressional levels were
demonstrated for CLDN-1 and OCLN in HCV-infected livers.4
These data suggest that CLDN-1 and OCLN expression may
be significantly influenced at post-transcriptional level in the
presence of HCV.
Dysregulated microRNA expression patterns have been
reported in many human diseases, such as various types of cancers,
as well as metabolic, infectious, chronic inflammatory, and
autoimmune diseases.24,25
Regarding HCV infection, the liver-specific miR-122 has been
reported to enhance HCV replication in human hepatoma cells by
binding to the 5′ UTR of HCV, and sequestration of miR-122 by
antisense oligonucleotide decreased HCV replication and transla-
tion in vitro16,23,26–28 and in vivo.29,30 However, no31 or only weak
positive correlation13 could be found between hepatic miR-122 and
F Gelley et al. MicroRNA profile
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serum HCV load, while no correlation could be observed between
hepatic miR-122 and hepatic HCV load.13,31 Further, miR-122 was
downregulated in acute HCV infection in human hepatoma cells
at day 4 post-infection,9 and IFN-β reduced the expression of
miR-122.17 This indicates that miR-122 may be affected by the
consequences of HCV infection and IFN treatment. In the present
study, higher expression level of miR-122 was associated with
higher viral load in patient sera; however, no significant difference
was found in hepatic miR-122 expression at the time of HCV
recurrence compared with normal liver tissue.
Applying the same comparison, the expression levels of miR-21
and miR-194 were decreased, whereas those of miR-99a* and
miR-224 were increased upon HCV reactivation when compared
with the normal hepatic expression of these miRs. miR-21 and
miR-194 were found to influence CLDN-1 mRNA expression,
while miR-99a* might control SCARB-1 expression and miR-224
might modulate mRNA of OCLN. In silico sequence comparison
also suggests the binding of miR-194 to mRNAs of OCLN and
CD81. Therefore, the observed expressional increase of CLDN-1
and OCLN4,5 might be caused by the decrease of miR-194 and
Table 2 MicroRNA expressions
A. MicroRNA expression at HCV recurrence compared with normal liver tissue
MicroRNA Relative expression Mean ratio (r/d) P value
Donor samples HCV-infected samples
miR-21 198.7 ± 89.6 46.8 ± 30.6 0.23 < 0.001
miR-96 0.0045 ± 0.0044 0.0018 ± 0.0016 0.4 NS
miR-99a* 0.25 ± 0.13 0.82 ± 0.74 3.28 0.002
miR-122 2005 ± 1586 1280 ± 1910 0.63 NS
miR-125b 28.7 ± 13.7 35.5 ± 35.3 1.18 NS
miR-181a-2* 0.15 ± 0.15 0.19 ± 0.16 1.2 NS
miR-194 157.3 ± 89.8 37.6 ± 35.2 0.24 < 0.001
miR-195 15 ± 8 11.2 ± 10.8 0.74 NS
miR-217 0.018 ± 0.01 0.013 ± 0.02 0.72 NS
miR-221 0.64 ± 0.48 0.34 ± 0.35 0.53 NS
miR-224 0.12 ± 0.1 0.24 ± 0.23 2.18 0.039
B. MicroRNA expression before and after antiviral therapy
MicroRNA Relative expression Mean ratio (a/b) P value
Before After
miR-21 46.8 ± 25.6 32.17 ± 37.3 0.68 NS
miR-96 0.0018 ± 0.0018 0.008 ± 0.007 4.4 NS
miR-99a* 0.8 ± 0.64 1.1 ± 1.3 1.3 NS
miR-122 1280 ± 1717 1219 ± 1914 0.9 NS
miR-125b 35.5 ± 36.8 43.8 ± 42.3 1.2 NS
miR-181a-2* 0.19 ± 0.18 0.26 ± 0.27 1.3 NS
miR-194 37.6 ± 36.4 46 ± 38.2 1.2 NS
miR-195 11.2 ± 11 7.86 ± 9.9 0.7 NS
miR-217 0.013 ± 0.1 0.023 ± 0.02 1.77 0.042
miR-221 0.34 ± 0.36 0.73 ± 0.43 2.1 0.006
miR-224 0.24 ± 0.2 0.72 ± 0.88 3 0.022
C. MicroRNA expression after antiviral therapy in SVR and NR group
MicroRNA Relative expression Mean ratio (a/b) P value
Before After
miR-21 30.8 ± 36 70.1 ± 110 2.3 NS
miR-96 0.006 ± 0.005 0.12 ± 0.18 20 0.01
miR-99a* 0.57 ± 0.57 3.14 ± 4.7 5.5 0.034
miR-122 1565.3 ± 2039 11 103.8 ± 16 666 7 0.014
miR-125b 39.2 ± 43.4 14.4 ± 12.4 0.36 NS
miR-181a-2* 0.14 ± 0.19 0.63 ± 0.76 4.5 0.017
miR-194 35.7 ± 27.4 50.8 ± 57.2 1.4 NS
miR-195 6.4 ± 7.2 22.9 ± 49.5 3.6 NS
miR-217 0.024 ± 0.025 3.7 ± 7.3 185 0.045
miR-221 0.8 ± 0.6 6.72 ± 10 8.4 0.003
miR-224 0.72 ± 0.8 0.51 ± 0.3 0.7 NS
HCV, hepatitis C virus; miR, microRNA; NR, non-responder; NS, non-significant; SVR, sustained virological response.
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miR-21 expressions upon HCV infection. This would represent
in vivo function of these miRs in the post-transcriptional regulation
of HCV receptors.
The high expression of miR-194 in normal liver tissue has been
known for a long time.32 miR-194 plays a role in the regulation of
hepatic stellate cell activation during fibrogenesis33 and suppresses
N-cadherin expression, leading to inhibition of cell migration,
adhesion, and metastasis of hepatocellular carcinoma (HCC)
cells.32 miR-21 has been previously identified as an “onco-miR”
because of its abberant expression in multiple malignancies
including breast cancer, colon, and HCCs.34 Interestingly, our
dataset showed decreased HCV recurrence-associated expression
of miR-21. Certain other changes, however, such as elevated
miR-224 expression found in our study during HCV recurrence,
were also detected in HCCs induced by HCV infection.35
Upregulated miR-224 was found in HCC cell lines and HCCs.
Recently, Scisciani and colleagues demonstrated that lipopolysac-
charide, lymphotoxin-α, and tumor necrosis factor-α inflamma-
tory pathways activated miR-224 expression. In addition, these
authors identified p65/NFκB as a direct transcriptional regulator of
miR-224 expression.36 In our study, increased expression of miR-
224 upon HCV reactivation is in accordance with the findings of
Scisciani and colleagues,36 as NFκB-dependent inflammatory
pathway is a key process during HCV infection.37
Increased expressions of miR-221, miR-224, and miR-217
were observed in samples taken after administration of IFN/RBV
treatment as compared with the pretreatment samples. miR-224
was able to recognize OCLN as a target mRNA. miR-221
expression is dysregulated in HCC38 and is suggested to be
affected by HCV and IFN. Liu and colleagues demonstrated that
miR-221 was downregulated after HCV exposure, and the gain
of miR-221 enhanced HCV RNA abundance in a dynamic in
vitro HCV infection system.9 Zhang and colleagues knocked
down miR-221 and miR-222 in glioblastoma cells and reported
that IFN-α was the most significantly affected signaling
pathway.39 Interestingly, we found that miR-221 expression level
negatively correlated with HAI. miR-217 was previously shown
to potentially predict therapy response in chronic HCV-infected
Figure 1 Hepatic expression of microRNAs
in normal liver tissue and in liver transplanted
patients at hepatitis C virus (HCV) recurrence
and after interferon/ribavirin therapy. Variables
are shown as mean values and standard error
of means (SEM). * symbolizes significant dif-
ference (P < 0.05). (a) Relative expression rate
of microRNAs at HCV recurrence in liver-
transplanted patients and in normal liver
tissue. Black bars represent normal donor
samples (n = 13), and white bars represent
biopsies obtained at HCV recurrence (n = 28).
(b) Relative expression rate of microRNAs
before and after interferon/ribavirin therapy
in liver-transplanted patients. Black bars
represent biopsies obtained before antiviral
therapy, and white bars represent samples
taken after antiviral therapy. (c) Relative
expression rate of microRNAs after
interferon/ribavirin therapy in sustained viral
response (SVR) and non-responder (NR)
groups. Black bars represent biopsies of non-
responder patients, and white bars show
biopsies of patients who reached SVR after
antiviral treatment. miR, microRNA.F
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patients40 and was found to be related to tumor differentiation
as well.14
We observed relevant alterations of microRNA expressions in
the SVR group, whereas microRNA expression levels remained
stable in non-responders after IFN/RBV treatment in comparison
with pretreatment levels. Partial responders following comple-
ted antiviral therapy were only three patients; therefore, these
patients were analyzed together within the NR group. It was
recently revealed that hepatic microRNA expression could be
associated with drug response3; however, our study did not reveal
a predictive value of pretreatment microRNA levels, including
miR-122, for the success of IFN/RBV treatment. Previously,
Sarasin-Filipowicz and colleagues demonstrated markedly
decreased pretreatment miR-122 levels in patients who had no
virological response during later IFN therapy.31 Estrabaud and
colleagues reported deregulated miR-99a*, miR-181a-2*, miR-
23a, and miR-217 in non-responders compared with patients
with later SVR.40 In contrast, our study revealed upregulated
miR-96, miR-99a*, miR-122, miR-181a-2*, miR-217, and miR-
221 expressions after IFN/RBV treatment in the SVR group
when compared with the NR group. In addition, following
antiviral treatment, miR-221 and miR-122 levels were higher
in SVR when compared with pretreatment levels. This suggests
that antiviral therapy restored miR-122 expression in SVR
patients. miR-122 is considered a differentiation and homeostatis
marker in hepatocytes.41 Given that miR-221 is suggested
to be oncogenic in HCC and miR-122 is crucial for HCV
proliferation, this phenomenon further strengthens the
complex way how miRs take action and rules out simple
mechanistic explanations. There were no statistical differences
in therapy response or microRNA expression between the
patient groups being either on tacrolimus or cyclosporin based
immunosuppression.
The interpretation of our study has some limitations. By the
clinical point of view, all of the considered patients belonged to
genotype 1/b; therefore, we might draw conclusions regarding
only to this patient group. Another point is that the normal liver
samples did not derive from the same transplanted liver because
the transplantation protocol of our institute did not contain zero
time point liver biopsy in the time frame of the study. The normal
liver samples were received from other donor livers harvested
before the start of this project. However, the donor selection cri-
teria for the transplantation remained the same.
In conclusion, we demonstrated that HCV recurrence and anti-
viral therapy is associated with altered hepatic expression of
miRs including those microRNAs, which potentially target
mRNAs of HCV receptors. Our data suggest that particularly
miR-194 and miR-21 may be involved in expressional regulation
of HCV receptor proteins during HCV infection and antiviral
therapy.
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